AI Article Synopsis
- A systematic review and meta-analysis compared the effectiveness of carfilzomib/lenalidomide/dexamethasone (KRd) versus bortezomib/lenalidomide/dexamethasone (VRd) for newly-diagnosed multiple myeloma, involving 1597 patients.
- KRd showed similar survival rates to VRd but resulted in higher complete response rates and more cases of measurable residual disease negativity.
- In patients with high-risk cytogenetics, KRd significantly improved progression-free survival, indicating its potential advantage for this specific group.
Article Abstract
In view of the increasing data evaluating carfilzomib-based induction for newly-diagnosed multiple myeloma (NDMM), we conducted a systematic review and meta-analysis comparing the efficacy of carfilzomib/lenalidomide/dexamethasone (KRd) versus bortezomib/lenalidomide/dexamethasone (VRd). Three studies totaling 1597 patients (50% KRd-treated, 50% VRd-treated) were included. Despite similar survival outcomes and overall response rate compared with the VRd arm, KRd-treated subjects showed higher odds of achieving complete responses and measurable residual disease negativity. Among patients with high-risk cytogenetics (n = 348), KRd was associated with significant improvement in progression-free survival (HR = 0.70; 95% CI = 0.50-0.97; p = .03; I = 0%), suggesting carfilzomib-based induction may be preferable in this NDMM subpopulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!